Acquisition - March 23, 2015
Deal for Genmab Holding, iDD
Genmab Holding B.V. a subsidiary of Genmab A/S, entered into an agreement to purchase antibodies and related patents from iDD Biotech SAS. The pre-clinical stage antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. Under the terms of the agreement, Genmab is expected to pay iDD Biotech EUR 2.5 […]
Uncategorized - March 17, 2015
Scientists Take Aim at HIV
A team of scientists from Denmark, America and Germany is hoping to wipe out the HIV virus by combining two types of medicine in a “super cocktail” that is extremely toxic to the resilient HIV virus. “It’s a very important step on the way to finding a cure for HIV,” says project leader Ole Søgaard, […]
